[{"NetIncomeLossConverted_1_Q1_USD":-39500000.0,"StockholdersEquityConverted_0_Q1_USD":875200000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":76000000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_1_Q1_USD":71800000.0,"EarningsPerShareDiluted_1_Q1_USD":-0.52,"CommonStockSharesOutstanding_0_Q1_shares":76700000.0,"StockholdersEquity_0_Q1_USD":875200000.0,"RevenuesConverted_1_Q1_USD":173100000.0,"Assets_0_Q1_USD":1336900000.0,"CommonStockSharesConverted_0_Q1_shares":76700000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":76000000.0,"EarningsPerShareBasic_1_Q1_USD":-0.52,"Ticker":"MYGN","CIK":"899923","name":"MYRIAD GENETICS INC","OfficialName":"Myriad Genetics Inc. Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1850258412.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20210505"}]